Clinical Trial Update: A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A [Phase 3]

View source ↗

Summary

Phase 3 study evaluating PXT3003 in Charcot-Marie-Tooth disease type 1A has completed. The document summarizes the completion status of the trial rather than pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Charcot-marie-tooth Disease Type 1a

Drugs mentioned

• PXT3003

Snippet

Sponsor: Tasly GeneNet Pharmaceuticals Co., Ltd | Conditions: Charcot-Marie-Tooth Type 1A | Phase 3 | Status: COMPLETED